Brimonidine (Ophthalmic)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Open-angle glaucoma — IOP reduction | Adults and children ≥2 years | Monotherapy or adjunctive | FDA Approved |
| Ocular hypertension — IOP reduction | Adults and children ≥2 years | Monotherapy or adjunctive | FDA Approved |
| Ocular redness relief (0.025% only — Lumify) | Adults and children ≥5 years | As needed (OTC) | FDA Approved (OTC) |
Brimonidine is a relatively selective alpha-2 adrenergic agonist that lowers IOP through a dual mechanism: reducing aqueous humour production and increasing uveoscleral outflow. It has a favourable cardiovascular and pulmonary safety profile compared with topical beta-blockers, making it an important alternative in patients with asthma, COPD, or cardiac contraindications to timolol. In clinical studies, brimonidine effectively lowers IOP by approximately 2–6 mmHg in patients with open-angle glaucoma or ocular hypertension. Brimonidine is commonly used as second- or third-line monotherapy, as adjunctive therapy with prostaglandin analogues or beta-blockers, and is available in several fixed-dose combinations (brimonidine/timolol, brimonidine/brinzolamide).
Neuroprotection in glaucoma: Preclinical studies have shown that brimonidine promotes retinal ganglion cell survival independent of IOP lowering via alpha-2 receptor-mediated upregulation of neurotrophic factors. The Low-Pressure Glaucoma Treatment Study suggested a possible neuroprotective benefit in normal-tension glaucoma, but definitive clinical evidence remains limited. (Evidence quality: Low)
Prevention of IOP spikes after laser procedures: Brimonidine 0.2% administered before and/or after Nd:YAG laser capsulotomy or argon laser trabeculoplasty to attenuate post-procedure IOP elevations. (Evidence quality: Moderate)
Brimonidine Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Open-angle glaucoma or ocular hypertension — adult monotherapy (0.1% or 0.15%) | 1 drop in affected eye(s) TID (~8 hours apart) | Same as starting dose | 1 drop TID | Alphagan P 0.15% is equivalent in IOP lowering to Alphagan 0.2% with potentially improved tolerability Peak IOP effect at 2 hours post-dosing (FDA PI) |
| Open-angle glaucoma or ocular hypertension — adult monotherapy (0.2%) | 1 drop in affected eye(s) TID (~8 hours apart) | Same as starting dose | 1 drop TID | Original formulation; preserved with BAK; higher rate of ocular allergy than 0.1%/0.15% Expected IOP reduction: 2–6 mmHg |
| Adjunctive therapy — with prostaglandin analogue, beta-blocker, or CAI | 1 drop TID (~8 hours apart) | Same as starting dose | 1 drop TID | Separate all topical ophthalmic drops by at least 5 minutes Additive IOP lowering when combined with other classes |
| Pediatric glaucoma — children ≥2 years | 1 drop in affected eye(s) TID | Same as starting dose | 1 drop TID | High somnolence risk: 50–83% in ages 2–6; ~25% in ages ≥7 Contraindicated in children <2 years — risk of apnoea, CNS depression |
| Ocular redness relief — OTC use (0.025% Lumify) | 1 drop in affected eye(s) every 6–8 hours | As needed, up to 4 times daily | 4 drops/day | Approved for adults and children ≥5 years (OTC) Not for glaucoma treatment; different concentration and indication |
Allergic conjunctivitis is one of the most common reasons for brimonidine discontinuation, occurring in 10–20% of patients on the 0.2% formulation and often developing after weeks to months of use (delayed hypersensitivity). The reformulated Alphagan P products (0.1% and 0.15%), which use the preservative Purite (stabilised oxychloro complex) instead of benzalkonium chloride, demonstrate comparable IOP-lowering efficacy with a lower incidence of ocular allergy. Switching from 0.2% to 0.15% may salvage therapy in patients who develop contact allergy to the BAK-containing formulation.
Administration Guidance
Remove contact lenses before instillation and wait at least 15 minutes before reinserting (applies to BAK-containing formulations). When using multiple topical ophthalmic products, separate each by at least 5 minutes. Instruct patients to apply nasolacrimal occlusion (gentle pressure on the inner corner of the eye) for 1 minute after instilling the drop to minimise systemic absorption, particularly in paediatric patients. Store at 15–25°C.
Pharmacology
Mechanism of Action
Brimonidine tartrate is a relatively selective alpha-2 adrenergic receptor agonist with approximately 1,000-fold selectivity for alpha-2 over alpha-1 receptors. Its ocular hypotensive effect is mediated through a dual mechanism. First, activation of alpha-2 receptors on the ciliary epithelium suppresses cyclic AMP production, reducing aqueous humour secretion. Second, brimonidine increases uveoscleral (non-conventional) outflow, an effect demonstrated in fluorophotometric studies in both animals and humans. The peak ocular hypotensive effect occurs approximately 2 hours after instillation. Unlike beta-blockers, brimonidine has minimal effect on cardiovascular and pulmonary parameters in adults, making it suitable for patients with asthma, COPD, or cardiac conduction disease. Additionally, preclinical research has identified alpha-2 receptor-mediated neuroprotective effects on retinal ganglion cells, including upregulation of brain-derived neurotrophic factor (BDNF).
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Primarily corneal; plasma Cmax = 73 ± 19 pg/mL after 0.15% single dose; Tmax = 1.7 ± 0.7 h; systemic levels are low (pg/mL range) | Low systemic exposure explains the minimal cardiovascular and pulmonary effects in adults; however, sufficient absorption occurs to cause CNS effects (drowsiness) especially in children |
| Distribution | Protein binding ~29%; crosses the blood-brain barrier; crosses the placenta to a limited extent in animal studies | CNS penetration accounts for the drowsiness, fatigue, and somnolence reported in clinical trials; higher risk in young children due to lower body mass |
| Metabolism | Extensive hepatic metabolism; in vitro data from human microsomal fractions and liver slices confirm extensive liver processing; specific CYP enzymes not fully characterised | Rapid systemic clearance limits accumulation; hepatic impairment not studied — use with caution |
| Elimination | Plasma t½ ~2–3 h (2.1 h for 0.15%, ~3 h for 0.2%); renal excretion is primary route; ~87% eliminated within 120 h (oral dose), 74% in urine | Short half-life necessitates TID dosing for sustained IOP control; not studied in renal impairment |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Oral dryness | ~33% | Most frequently reported systemic effect; due to alpha-2 agonist activity on salivary glands; usually mild and tolerable |
| Ocular / conjunctival hyperemia | 10–30% | May occur on instillation; paradoxical given the vasoconstrictive mechanism; may represent rebound effect |
| Burning and stinging | 10–30% | Transient on instillation; may be reduced with Purite-preserved formulations (0.1%/0.15%) |
| Headache | 10–30% | Systemic alpha-2 agonist effect; usually mild and self-limiting |
| Blurred vision | 10–30% | Transient; resolves within minutes of instillation |
| Foreign body sensation | 10–30% | Local ocular irritation; typically improves with continued use |
| Fatigue / drowsiness | 10–30% | CNS effect due to alpha-2 agonist crossing blood-brain barrier; particularly pronounced in young children |
| Conjunctival follicles | 10–30% | Follicular response in inferior fornix; may indicate developing allergic reaction |
| Ocular allergic reactions / allergic conjunctivitis | 10–20% | Delayed-type (type IV) hypersensitivity; may develop after weeks to months; leading cause of discontinuation; lower rate with Purite-preserved formulations |
| Ocular pruritus | 10–30% | May signal developing allergic conjunctivitis; consider switching formulation or discontinuing |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Corneal staining / erosion | 3–9% | May be related to preservative exposure; consider preservative-free options if persistent |
| Photophobia | 3–9% | Mild; advise sunglasses if bothersome |
| Eyelid erythema / edema | 3–9% | May indicate allergic contact dermatitis |
| Ocular dryness / tearing | 3–9% | Variable; either dryness or reflex tearing reported |
| Upper respiratory symptoms | 3–9% | Systemic effect; nasal dryness also reported |
| Dizziness / hypertension | 3–9% | Paradoxical hypertension reported in some patients despite alpha-2 agonist class effect |
| Asthenia / blepharitis | 3–9% | General fatigue; blepharitis may require lid hygiene measures |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe paediatric CNS depression (apnoea, bradycardia, coma, hypothermia, hypotonia, respiratory depression) | Reported in infants <2 years (postmarketing) | Within hours of administration | Drug is contraindicated in children <2 years; if accidental exposure in an infant, immediate emergency care; monitor airway, breathing, circulation |
| Severe somnolence in children 2–6 years | 50–83% (ages 2–6 in controlled trial) | Within hours; recurs with each dose | ~16% of paediatric patients discontinued due to somnolence; closely monitor; consider alternative IOP-lowering agent; less frequent in children ≥7 years (~25%) |
| Syncope / hypotension | <3% (postmarketing) | Variable | Assess blood pressure; use with caution in patients on antihypertensives; consider discontinuation |
| Severe ocular allergy (requiring discontinuation) | 10–20% develop; subset requires drug cessation | Weeks to months (delayed hypersensitivity) | Discontinue brimonidine; switch to alternative IOP-lowering class; symptoms typically resolve within 1–2 weeks of cessation |
| Depression | <3% | Variable | Use with caution in patients with pre-existing depression; consider alternative agent if new or worsening depressive symptoms develop |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Ocular allergic reaction / allergic conjunctivitis | Most common adult reason | Delayed-type (type IV) hypersensitivity; typically develops after 3–9 months of continuous use; lower rate with Purite-preserved formulations |
| Somnolence (paediatric) | ~16% | Primary reason for discontinuation in children 2–7 years on 0.2% TID in controlled trials (FDA PI) |
The hallmark of brimonidine allergy is a delayed-onset (type IV) hypersensitivity reaction characterised by follicular conjunctival response, eyelid erythema, pruritus, and ocular discomfort typically appearing 3–9 months after initiating therapy. This allergic reaction is distinct from the transient burning and stinging on instillation. When allergy develops, the drug must be discontinued — symptoms usually resolve within 1–2 weeks. Some patients may tolerate the Purite-preserved 0.15% or 0.1% formulations, though cross-reactivity to the brimonidine molecule itself (rather than preservative) is possible and should be monitored.
Drug Interactions
Brimonidine is an alpha-2 adrenergic agonist with extensive hepatic metabolism. Its interaction profile is predominantly pharmacodynamic — additive CNS depression and cardiovascular effects with concurrent sedating or hypotensive agents. MAO inhibitor co-administration is contraindicated.
Monitoring
-
Intraocular Pressure
Baseline; at 2–4 weeks; then every 3–6 months
Routine Note that the first month of therapy may not reflect long-term IOP reduction. Peak IOP lowering occurs ~2 hours after dosing; measure at consistent time relative to last dose. Expected reduction: 2–6 mmHg. -
Ocular Surface / Allergy Signs
Each visit; especially months 3–9
Routine Monitor for follicular conjunctival response, lid erythema, pruritus, and contact allergy. Peak risk period for developing delayed hypersensitivity is 3–9 months. Discontinue if confirmed allergic conjunctivitis develops. -
Drowsiness / CNS Effects (Paediatric)
At initiation and each visit
Routine Enquire about somnolence, lethargy, and decreased alertness in all paediatric patients. Somnolence occurs in 50–83% of children aged 2–6 years. Educate caregivers to observe for excessive sleepiness. -
Blood Pressure
Baseline; then if symptomatic
Trigger-based Although brimonidine had minimal effect on blood pressure in clinical studies, caution in patients on antihypertensives or with severe cardiovascular disease. Monitor if dizziness or syncope reported. -
Mood Assessment
Each visit; patient self-report
Trigger-based Use with caution in patients with depression. Alpha-2 agonists can exacerbate depressive symptoms through central noradrenergic mechanisms. Ask about low mood, insomnia, and anxiety. -
Visual Fields
Per glaucoma guidelines (every 6–12 months)
Routine Standard automated perimetry to detect glaucomatous progression. Not specific to brimonidine but essential for overall glaucoma management.
Contraindications & Cautions
Absolute Contraindications
- Neonates and infants (<2 years of age) — risk of severe CNS and respiratory depression including apnoea, bradycardia, coma, hypothermia, and hypotonia (FDA PI Section 4.1)
- Hypersensitivity to brimonidine tartrate or any component of the formulation (FDA PI Section 4.2)
- Concurrent MAO inhibitor therapy — risk of severe hypotension and exaggerated systemic effects (certain formulations list this as a formal contraindication)
Relative Contraindications (Specialist Input Recommended)
- Children aged 2–6 years — while not formally contraindicated, very high rates of somnolence (50–83%) and 16% discontinuation rate make use challenging; careful risk-benefit assessment required
- Severe cardiovascular disease — although brimonidine has minimal cardiovascular effects in studies, caution is warranted
- Pregnancy — brimonidine crosses the placenta in animal studies; miscarriage observed at doses approximately 70 times the RHOD; use only if benefit clearly justifies risk
- Hepatic or renal impairment — not studied; brimonidine undergoes extensive hepatic metabolism; use with caution
Use with Caution
- Depression — alpha-2 agonists may exacerbate depressive symptoms
- Cerebral or coronary insufficiency — may potentiate vascular insufficiency syndromes
- Raynaud’s phenomenon — alpha-2 agonist class effect may worsen peripheral vasoconstriction
- Orthostatic hypotension — additive hypotensive potential
- Thromboangiitis obliterans — vascular insufficiency risk
- Contact lens wearers — remove before instillation; wait 15 minutes before reinserting (BAK-containing formulations)
- Breastfeeding — brimonidine excreted in breast milk in animal studies; risk of CNS depression and apnoea in nursing infants; not recommended during lactation
Brimonidine is contraindicated in neonates and infants (younger than 2 years). During postmarketing surveillance, apnoea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence have been reported in infants receiving brimonidine, including cases of accidental oral ingestion. These reactions can be life-threatening. Even in children aged 2–6 years, somnolence rates of 50–83% have been documented in controlled studies, with approximately 16% of children discontinuing therapy due to excessive sedation. Extreme caution is required when prescribing brimonidine to any paediatric patient.
Patient Counselling
Purpose of Therapy
Brimonidine eye drops are prescribed to lower the pressure inside the eye, which helps protect the optic nerve and prevent vision loss from glaucoma. The medication controls the condition but does not cure it, and it must be used consistently three times daily, approximately 8 hours apart. Do not stop using brimonidine without speaking to your eye doctor.
How to Take
Instil one drop into the affected eye(s) three times daily, about 8 hours apart. After instilling each drop, close the eye gently and press a fingertip against the inner corner of the eye near the nose for 1 minute to reduce absorption into the bloodstream. If using other eye drops, wait at least 5 minutes between each. Remove contact lenses before use and wait 15 minutes before reinserting.
Sources
- Alphagan P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15% — Full Prescribing Information (AbbVie/Allergan). Revised 2025. accessdata.fda.gov Current PI for Alphagan P; primary source for dosing, adverse reactions (5–20% range), paediatric safety data, contraindications, and PK parameters.
- Alphagan (brimonidine tartrate ophthalmic solution) 0.5% — Full Prescribing Information (AbbVie). Revised 2025. accessdata.fda.gov Original Alphagan formulation PI (NDA 020490); provides the 10–30% adverse reaction data from early controlled trials and postmarketing paediatric safety reports.
- Brimonidine tartrate ophthalmic solution 0.2% — Full Prescribing Information (generic). drugs.com Generic 0.2% PI with pharmacokinetic data (Tmax, t½, urinary excretion) and full adverse reaction profile.
- Brimonidine tartrate ophthalmic solution 0.15% — Full Prescribing Information (Alcon/Sandoz). accessdata.fda.gov Generic 0.15% PI with detailed PK study data (Cmax 73 pg/mL, Tmax 1.7 h, t½ 2.1 h, protein binding 29%).
- Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K; Chronic Brimonidine Study Group. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension: a controlled, randomized, multicenter clinical trial. Arch Ophthalmol. 1997;115(7):847–852. PMID: 9230823. Pivotal 1-year RCT establishing brimonidine 0.2% BID as comparable to timolol 0.5% BID in IOP-lowering efficacy with a different side-effect profile.
- Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S; Low-Pressure Glaucoma Treatment Study Group. A randomized trial of brimonidine versus timolol in preserving visual function. Am J Ophthalmol. 2011;151(4):671–681. PMID: 21257146. LPTG Study suggesting possible neuroprotective benefit of brimonidine in low-pressure glaucoma; fewer visual field progressions vs timolol.
- European Glaucoma Society. Terminology and Guidelines for Glaucoma. 5th Edition. 2020. eugs.org EGS guidelines positioning alpha-2 agonists as second- or third-line agents for open-angle glaucoma.
- American Academy of Ophthalmology. Preferred Practice Pattern: Primary Open-Angle Glaucoma. 2020. aao.org US guideline discussing brimonidine as adjunctive therapy or alternative when beta-blockers are contraindicated.
- Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113(12):1514–1517. PMID: 7487619. Fluorophotometry study demonstrating brimonidine’s dual mechanism of action: aqueous suppression and increased uveoscleral outflow in humans.
- WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42(12):2849–2855. PMID: 11687528. Key preclinical study demonstrating brimonidine’s alpha-2 receptor-mediated neuroprotection of retinal ganglion cells in an animal model of glaucoma.
- Acheampong AA, Shackleton M, Tang-Liu DD, Ding S, Stern ME, Decker R. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos. 1995;23(7):708–712. PMID: 7587958. Ocular PK study in rabbits demonstrating rapid corneal absorption, melanin binding in iris-ciliary body, and the depot effect in pigmented tissues.
- Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006;2(4):337–346. PMCID: PMC1936355. Comprehensive review of brimonidine pharmacology, clinical efficacy across formulations, neuroprotection data, and tolerability profile.
- Levy Y, Zadok D. Systemic side effects of ophthalmic drops. Clin Pediatr (Phila). 2004;43(1):99–101. PMID: 14968901. Case series documenting life-threatening systemic effects of ophthalmic brimonidine in young children, supporting the age-based contraindication.
- Mundorf T, Noecker RJ, Earl M; ADAPT Study Group. A comparison of brimonidine tartrate 0.15% with brimonidine tartrate 0.2% in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2003;19(1):37–44. PMID: 12648302. Comparative study showing equivalent IOP reduction between 0.15% (Purite-preserved) and 0.2% (BAK-preserved) formulations, with lower ocular allergy rates for the 0.15% product.